Guideline / position statementindependent cross-checkabstract only checked I-ODD-17 standard review

ADA/EASD consensus 2022

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Overview

Davies MJ et al.. Diabetes Care 2022 · PMID 36148880 · DOI 10.2337/dci22-0034

Weight management plus heart- and kidney-protective drugs are central to type 2 diabetes care.

Does the study support the specific claim? No · Methodological quality: high

Original publication

Plain-language summary

Study explained simply

What did the researchers want to find out?: Management of hyperglycaemia in type 2 diabetes
How was the study done?: ADA/EASD consensus report based on systematic examination of publications since 2018
How many people, animals or samples were studied?: not applicable; Adults with type 2 diabetes
What was actually found?: Cardiorenal protection and weight focus.
How large was the observed effect?: not applicable
What do the results mean in everyday life?: Guideline direction.
What are the study's limitations?: Abstract only read
What does it say about Elawady's specific claim?: Contradicts C-ODD-06; supports C-INS-11.
Do the results apply to Germany and Europe?: EASD co-authored; directly applicable to EU.
What can explicitly not be concluded from this study?: Not applicable.

Scientific in-depth review

1. Full reference

Authors: Davies MJ et al.
Journal: Diabetes Care
Year: 2022
Identifier: PMID 36148880 DOI 10.2337/dci22-0034
Verification: verified – PubMed efetch 2026-10-25 (this agent)
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: not stated in abstract

2. Research question

Management of hyperglycaemia in type 2 diabetes

3. Study design and population

Study design: Guideline / position statement – ADA/EASD consensus report based on systematic examination of publications since 2018
Population: Adults with type 2 diabetes
Country: USA and Europe
Period: 2022
Sample size: not applicable
Inclusion and exclusion criteria: As described in the abstract; details not available in abstract.

4. Methods and endpoints

Exposure / intervention: not applicable
Comparator: not applicable
Endpoints: not applicable
Statistical methods: Consensus

5. Actual results

Results: Abstract: greater emphasis on weight management; results of CV and kidney outcome trials of SGLT2 inhibitors and GLP-1 RAs inform broader recommendations for cardiorenal protection in people at high risk.
Absolute risks: not reported
Authors' conclusion: Holistic, person-centred management with cardiorenal protection.

6. Strengths

Joint US-European consensus

7. Weaknesses

Abstract only read

8. Risk of bias

Orienting tool: none applicable
Type of assessment: simplified assessment (abstract only)
Full formal assessment: no
Overall risk of bias: low
Rationale: Guideline.

9. Assessment of the statistical interpretation

not applicable

10. Relevance to the specific claim

Contradicts C-ODD-06; supports C-INS-11.

11. Independent contrary findings

12. Transferability to Germany and Europe

EASD co-authored; directly applicable to EU.

13. Overall methodological judgement

Current consensus.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	high
Risk of bias	low
Precision of results	not applicable
Directness	direct
Reproducibility	replicated
Consistency with the overall evidence	consistent
Regional transferability	high
Adequacy of the interpretation (by the archive)	not applicable

14. Open questions

None beyond those stated.